ArticleNature reviews. Drug discovery2010
Ofatumumab.
Article in Nature reviews. Drug discovery, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20Scientific reports · 2021Pooled it
- Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia.The Cochrane database of systematic reviews · 2012Pooled it
- Revisiting the Ofatumumab Epitope on CD20 through Integrative Molecular Dynamics and Flow Cytometry Analyses.Computational and structural biotechnology journal · 2026Article
- B-cell targeted therapies in autoimmune encephalitis: mechanisms, clinical applications, and therapeutic potential.Frontiers in immunology · 2024Review
- Pediatric NMOSD: A Review and Position Statement on Approach to Work-Up and Diagnosis.Frontiers in pediatrics · 2020Review
- Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better?Current oncology reports · 2018Review
- Successful use of ofatumumab in two cases of early-onset juvenile SLE with thrombocytopenia caused by a mutation in protein kinase C δ.Pediatric rheumatology online journal · 2018Article
- Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.Oncoimmunology · 2015Review
- Trial Watch: Immunostimulatory cytokines.Oncoimmunology · 2013Review
- Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
- New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come.Journal of central nervous system disease · 2012Article
- Trial Watch: Monoclonal antibodies in cancer therapy.Oncoimmunology · 2012Article
- Monoclonal antibodies - a proven and rapidly expanding therapeutic modality for human diseases.Protein & cell · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
20118960What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.